Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway - PubMed (original) (raw)

. 2009 Oct;30(10):1660-9.

doi: 10.1093/carcin/bgp178. Epub 2009 Jul 22.

Yu-Liang Ran, Hai Hu, Long Yu, Qian Liu, Zhuan Zhou, Yue-Min Sun, Li-Chao Sun, Jian Pan, Li-Xin Sun, Ping Zhao, Zhi-Hua Yang

Affiliations

• PMID: 19625348
• DOI: 10.1093/carcin/bgp178

Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway

Liang Peng et al. Carcinogenesis. 2009 Oct.

Abstract

The purpose of this study was to investigate invasion- and metastasis-related genes in gastric cancer. To this end, we used the transwell system to select a highly invasive subcell line from minimally invasive parent cells and compared gene expression in paired cell lines with high- and low-invasive potentials. Lysyl oxidase-like 2 (LOXL2) was overexpressed in the highly invasive subcell line. Immunohistochemical analysis revealed that LOXL2 expression was markedly increased in carcinoma relative to normal epithelia, and this overexpression in primary tumor was significantly associated with depth of tumor invasion, lymph node metastasis and poorer overall survival. Moreover, LOXL2 expression was further increased in lymph node metastases compared with primary cancer tissues. RNA interference-mediated knockdown and ectopic expression of LOXL2 showed that LOXL2 promoted tumor cell invasion in vitro and increased gastric carcinoma metastasis in vivo. Subsequent mechanistic studies showed that LOXL2 could activate both the Snail/E-cadherin and Src kinase/Focal adhesion kinase (Src/FAK) pathways. However, secreted LOXL2 induced gastric tumor cell invasion and metastasis exclusively via the Src/FAK pathway. Expression correlation analysis in gastric carcinoma tissues also revealed that LOXL2 promoted invasion via the Src/FAK pathway but not the Snail/E-cadherin pathway. We then evaluated secreted LOXL2 as a target for gastric carcinoma treatment and found that an antibody against LOXL2 significantly inhibited tumor growth and metastasis. Overall, our data revealed that LOXL2 overexpression, a frequent event in gastric carcinoma progression, contributes to tumor cell invasion and metastasis, and LOXL2 may be a therapeutic target for preventing and treating metastases.

PubMed Disclaimer

Similar articles

• Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
  Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C, Chiara MD. Canel M, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3272-9. doi: 10.1158/1078-0432.CCR-05-1583. Clin Cancer Res. 2006. PMID: 16740747
• Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway.
  Li RK, Zhao WY, Fang F, Zhuang C, Zhang XX, Yang XM, Jiang SH, Kong FZ, Tu L, Zhang WM, Yang SL, Cao H, Zhang ZG. Li RK, et al. J Cancer Res Clin Oncol. 2015 Feb;141(2):269-81. doi: 10.1007/s00432-014-1823-z. Epub 2014 Sep 14. J Cancer Res Clin Oncol. 2015. PMID: 25216702
• Signal transduction by focal adhesion kinase in cancer.
  Zhao J, Guan JL. Zhao J, et al. Cancer Metastasis Rev. 2009 Jun;28(1-2):35-49. doi: 10.1007/s10555-008-9165-4. Cancer Metastasis Rev. 2009. PMID: 19169797 Review.
• Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations.
  Schwartz GK. Schwartz GK. Semin Oncol. 1996 Jun;23(3):316-24. Semin Oncol. 1996. PMID: 8658215 Review.

Cited by

• Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling.
  Guo JL, Zheng SJ, Li YN, Jie W, Hao XB, Li TF, Xia LP, Mei WL, Huang FY, Kong YQ, He QY, Yang K, Tan GH, Dai HF. Guo JL, et al. World J Gastroenterol. 2012 Apr 14;18(14):1602-9. doi: 10.3748/wjg.v18.i14.1602. World J Gastroenterol. 2012. PMID: 22529688 Free PMC article.
• The effect of LOXL2 in hepatocellular carcinoma.
  Wu L, Zhang Y, Zhu Y, Cong Q, Xiang Y, Fu L. Wu L, et al. Mol Med Rep. 2016 Sep;14(3):1923-32. doi: 10.3892/mmr.2016.5474. Epub 2016 Jul 6. Mol Med Rep. 2016. PMID: 27430160 Free PMC article.
• Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.
  Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Schliekelman MJ, et al. Cancer Res. 2011 Dec 15;71(24):7670-82. doi: 10.1158/0008-5472.CAN-11-0964. Epub 2011 Oct 10. Cancer Res. 2011. PMID: 21987723 Free PMC article.
• LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
  Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, Lee HD, Green JE. Ahn SG, et al. Breast Cancer Res Treat. 2013 Aug;141(1):89-99. doi: 10.1007/s10549-013-2662-3. Epub 2013 Aug 10. Breast Cancer Res Treat. 2013. PMID: 23933800 Free PMC article.
• Lysyl oxidase like-2 in fibrosis and cardiovascular disease.
  Poe A, Martinez Yus M, Wang H, Santhanam L. Poe A, et al. Am J Physiol Cell Physiol. 2023 Sep 1;325(3):C694-C707. doi: 10.1152/ajpcell.00176.2023. Epub 2023 Jul 17. Am J Physiol Cell Physiol. 2023. PMID: 37458436 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal